A review of the antiepileptic drug tiagabine

Clinical Neuropharmacology

Volumn 22, Issue 6, 1999, Pages 312-317

  Schachter, Steven C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant; GABA; Monotherapy; Tiagabine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; TIAGABINE;

4 AMINOBUTYRIC ACID UPTAKE; ANTICONVULSANT THERAPY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MECHANISM; EPILEPSY; HUMAN; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; DRUG UTILIZATION; EPILEPSY; HUMANS; NIPECOTIC ACIDS;

EID: 0032703335     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res 1987;1:77-93.
2. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-(4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl)nipecotic acid binds with high affinity to the brain GABA uptake carrier. J Neurochem 1990;54:639-47.
3. Giardina WJ. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy 1994;7:161-6.
4. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
5. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:219-24.
6. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995;36 (suppl 6):7-9.
7. Morimoto K., Sato H, Yamamoto Y, Watanabe T, Suwaki H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997; 38:966-74.
8. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196: 257-66.
9. Faingold CL, Randall ME, Anderson CA. Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp Neurol 1994;126:225-32.
10. Suzdak PD. Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment. Epilepsy Res 1994;19: 205-13.
11. Pierce MW, Suzdak PD, Gustavson LE, et al. Tiagabine. In: Pisani F, Perucca E, Avansini G, Richens A, eds. New Antiepileptic Drugs. Amsterdam: Elsevier; 1991;157-60.
12. Mengel H. Tiagabine. Epilepsia 1994;35(suppl 5):81-4.
13. Bopp BA, Nequist GE, Rodrigues AD. Role of the cytochrome P450 3A subfamily in the metabolism of [14C] tiagabine by human hepatic microsomes [abstract]. Epilepsia 1995;36(suppl 2):159.
14. Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998;39:868-73.
15. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997;38:445-51.
16. Østergaard LH, Gram L, Dam M. Potential antiepileptic drugs. Tiagabine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York: Raven Press; 1995;1057-61.
17. Bopp B, Gustavson L, Johnson M, et al. Pharmacokinetics and metabolism of [14C tiagabine] after oral administration to human subjects [abstract]. Epilepsia 1995;36(suppl 2):158.
18. Cato A, Gustavson LE, Quian J, El-Shourbagy T, Kelly EA. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998;39:43-7.
19. Snel S, Jansen JA, Mengel HB, Richens A, Larsen S. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997;37:1015-20.
20. Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:1032-7.
21. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995;36(suppl 6):2-6.
22. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
23. Gustavson LE, Cato A, Guenther HJ, et al. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin, or valproate [abstract]. Epilepsia 1995;36(suppl 3):159.
24. Snel S, Jansen JA, Pedersen PC, Jonkman JH, van Heiningen PN. Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin. Eur J Clin Pharmacol 1998;54:355-7.
25. Gustavson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Am J Ther 1998;1:73-9.
26. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:141-50.
27. Mengel H, Jansen JA, Sommerville K, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol [abstract]. Epilepsia 1995;36(suppl 3):160.
28. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
29. Lassen LC, Sommerville K, Mengel HB, Edwards D, Nielsen B, Shu V. Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures [abstract]. Epilepsia 1995;36(suppl 3):148.
30. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
31. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures. Arch Neurol 1997;54:595-601.
32. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Epilepsy Res 1998;30:31-40.
33. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995;36(suppl 6):14-21.
34. Somerville E. Lack of aggravation of epilepsy by tiagabine [abstract]. Epilepsia 1998;39(suppl 6):127.
35. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
36. Biton V, Vasquez B, Sachdeo JC, Lenz GT, Sommerville KW. Adjunctive tiagabine compared to phenytoin and carbamazepine in the multicenter, double-blind trial of complex partial seizures. Epilepsia 1998;39(suppl 6):125-6.
37. Schachter SC, Deaton R, Sommerville K. Long-term use of tiagabine for partial seizures. Epilepsia 1997;38(suppl 8):105-6.
38. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36 (suppl 6):10-3.
39. Leppik IE, Gram L, Deaton R, Sommerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999;33:235-46.
40. Sommerville KW, Hearell M, Deaton R, Leppik IE. Adverse events with long-term tiagabine therapy [abstract]. Epilepsia 1997;38 (suppl 8):106.
41. Collins SD, Brun S, Kirstein YG, Sommerville KW. Absence of visual field defects in patients taking tiagabine. Epilepsia 1998;39 (suppl 6):146-7.
42. Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39:671-4.
43. Schachter SC, Cahill WT, Wannamaker BB, Shu VS, Sommerville KW. Open-label dosage and tolerabiliry study of tiagabine monotherapy in patients with refractory complex partial seizures. J Epilepsy 1998;11:248-55.
44. Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:33-42.
45. Collins SD, Donnelly J, Krupa D, Sommerville KW. Pregnancy and tiagabine exposure [abstract]. Neurology 1997;48(suppl 2):A38.
46. Willert C, Englisch S, Schlesinger S, Runge U. Possible drug-induced thrombocytopenia secondary to tiagabine [abstract]. Neurology 1999;52:888.
47. Trinka E, Moroder T, Nagler M, Staffen W, Loscher W, Ladurner G. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999;8:41-4.
48. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998;10:181-4.
49. Schachter SC. Tiagabine: current status and potential clinical applications. Exp Opin Invest Drugs 1996;5:1377-87.